Molbio Diagnostics

Salcete, India Founded: 2000 • Age: 26 yrs Listed
Point-of-care molecular platforms for infectious disease detection are developed.
Request Access
Report Incorrect Data
Page last updated

About Molbio Diagnostics

Molbio Diagnostics is a publicly listed company based in Salcete (India) founded in 2000 by Chandrasekhar Nair and Sriram Natarajan. Point-of-care molecular platforms for infectious disease detection are developed. Molbio Diagnostics has raised $123.98 million across 4 funding rounds from investors including Motilal Oswal, Motilal Oswal Financial Services and Temasek. The company has 714 employees. Molbio Diagnostics has completed 1 acquisition, including Prognosys Medical Systems. Molbio Diagnostics was last valued at $1.6 billion in September 2022. Its chief executive, as recorded, is Sriram Natarajan. Its Indian entity Molbio Diagnostics Limited reported revenue of ₹1,459 Cr. Molbio Diagnostics offers products and services including Truenat and Truenat Assays. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified.

Company details

Developer of point-of-care molecular diagnostic platform for infectious disease detection. The solution includes Trueprep a fully automatic universal cartridge-based sample prep device, Prolab Atlus portable x-ray system, Thermalytix AI-based thermal scanning device, and Truelab, a real-time, quantitative micro-PCR analyzer that targets diseases like rifampicin resistance, COVID19, influenza, dengue, hepatitis, HPV, malaria, and others.

Recognitions & Rankings of Molbio Diagnostics

India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#392
Valuation
₹13,580 Cr
2023 #310 2022 #275
  • Headquarters Salcete, India
  • Employees 714
  • Founders Chandrasekhar Nair, Sriram Natarajan
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    •••• ••••
  • Website molbiodiagnostics.com
  • Social LinkedIn X Facebook
  • Legal Name Molbio Diagnostics Limited
Operational Areas
Healthcare → Genomics & Gene Therapy Platforms
Healthcare → Infectious Diseases
Key Metrics
  • Market Cap
    ₹15,675 Cr

    MOLBIO · NSE

  • Share Price
    ₹1,336.00

    -1.78% today

  • Revenue
    ₹1,446 Cr

    FY 2025-26 · +41.7% YoY

  • EBITDA
    ₹315 Cr

    Margin 21.8%

  • Net Profit
    ₹167 Cr

    FY 2025-26 · +10.0% YoY

  • P/E (TTM)
    92.3x

    P/B 11.3x

  • ROE
    15.4%

    ROCE 19.1%

  • Debt / Equity
    0.28

    Interest cover 13.3x

  • Total Equity Funding
    $123.98M (USD)

    in 4 rounds

  • Investors
    Motilal Oswal

    & 16 more

  • Employee Count
    714
  • Investments & Acquisitions
    Prognosys Medical Systems

Products & Services of Molbio Diagnostics

Molbio Diagnostics offers a comprehensive portfolio of products and services, including Truenat and Truenat Assays.

Truenat
Diagnostic Platform

Portable real-time PCR device for detecting multiple infectious diseases

Truenat Assays
Diagnostic Tests

Assays for use with Truenat platform to identify pathogens

Funding Insights of Molbio Diagnostics

Molbio Diagnostics has successfully raised a total of $123.98M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $123.98M
  • Total Rounds 4
  • First Round $19.73M

    (Jan 2020)

  • Investors Count 17

All 4 funding rounds of Molbio Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2023Grant––
ACT Grants
Sep 2022$85MSeries C$1.6BTemasek
Motilal Oswal
May 2021$19.25MSeries B$225.05MMotilal Oswal
–
Jan 2020$19.73MSeries B$•••••Motilal Oswal
Shankar Gopalakrishnan
Valuation history
DateValuationStage
Sep 2022$1.6B••••••••
May 2021$225.05M••••••••
Jan 2020$•••••••••••••
Premium access

Full valuation and stage history of Molbio Diagnostics

Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.

  • All valuation points
  • Stage changes
  • Dates
  • Exports

Verified entity values are shown only after access is granted.

Last known valuation $1.6B (Sep 2022). 17 investors in total: 9 institutional and 8 angel.

Investors in Molbio Diagnostics

Molbio Diagnostics has secured backing from 17 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Motilal Oswal, Motilal Oswal Financial Services and Temasek.

All
Venture Fund
Institutional
Angel
InvestorDescriptionFounded YearDomainLocation
ACT Grants
Seed capital grants are provided to incubate and accelerate innovations.
2020actgrants.inBengaluru, India
Temasek
An investment platform is provided for diverse sectors and geographies.
1974temasek.com.sgSingapore, Singapore
Motilal Oswal Alternates
Motilal Oswal Alternates is engaged in alternative investment management.
motilaloswalalt.comMumbai, India
Rank Ventures
Venture capital firm focused on multiple sectors
rank-ventures.com
Motilal Oswal Private Equity
Private equity investment firm focused on growth stage companies
2006motilaloswalpe.comMumbai, India
Exxora Trading
Venture capital fund focused on multiple sectors
Lucky Investment Managers
Venture capital is invested in early-stage founders across Indian markets.
luckyinvestmentmanagers.comMumbai, India
Motilal Oswal
Online share trading and investment services are provided.
1987motilaloswal.comMumbai, India
Motilal Oswal Financial Services
Diversified investment and advisory services are provided to clients.
1987motilaloswalgroup.comMumbai, India

Shankar Gopalakrishnan

unknown_fbb351a9a48148ce8
Premium access

Investor details for Molbio Diagnostics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Molbio Diagnostics Limited (Molbio Diagnostics)

Molbio Diagnostics Limited is the primary company behind Molbio Diagnostics. The boards of the 2 registered companies of Molbio Diagnostics currently have 6 directors; the longest-serving is Chandrasekhar Bhaskaran Nair, appointed in 2011. 13 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Chandrasekhar Bhaskaran Nair
DIN 01787875
Director01 Aug 201115 yrs 3 moMolbio Diagnostics Limited
Sangeetha Sriram
DIN 02103165
Director19 Jun 20206 yrs 4 moMolbio Diagnostics Limited, Enesar Consulting Private Limited
Sriram Natarajan
DIN 00013843
CEO10 Jul 20233 yrs 4 moMolbio Diagnostics Limited, Enesar Consulting Private Limited
Arunkumar Jha
DIN 01235238
Director16 Nov 20241 yr 11 moMolbio Diagnostics Limited
Balram Bhargava
DIN 10479707
Director16 Nov 20241 yr 11 moMolbio Diagnostics Limited
Nupur Garg
DIN 03414074
Director31 Jan 20251 yr 9 moMolbio Diagnostics Limited

People of Molbio Diagnostics

10 people are tracked at Molbio Diagnostics (3 in leadership, 7 in team); the tracked headcount is 714.

NameRoleGroup
Chandrasekhar Nair
Co-Founder & CTOLeadership
Sriram Natarajan
Co-Founder & CEOLeadership
Sumit Mitra
President - International SalesLeadership
Amit Yadav
Senior Sales-application ExecutiveTeam
Amarjit singh Lohiya
Regional Sales ManagerTeam
Arindam Das
Sales OfficerTeam
Manu Dhama
Regional Sales ManagerTeam
Prabhanjan Reddy
Regional Sales ManagerTeam
Parixit Chavda
Regional Sales ManagerTeam
winnie gonsalves
Senior Executive International SalesTeam
Premium access

Complete people profiles for Molbio Diagnostics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Molbio Diagnostics

Molbio Diagnostics is a publicly listed company on the NSE with ticker symbol MOLBIO in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date17 Aug 2026
  • Listed onNSE: MOLBIO
  • Listed entityMolbio Diagnostics Limited
  • Exchange sectorHealth technology
  • ISININE869T01028
  • Share price₹1,470.10 (-0.12% on the day) · 2026-10-14
  • Market capitalisation₹16,954 Cr
  • Volume (last session)364,093

Financials of Molbio Diagnostics

Exchange-reported figures of Molbio Diagnostics Limited, the listed company behind Molbio Diagnostics (NSE: MOLBIO).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,446 Cr
+41.7% YoY
EBITDA
₹315 Cr
+27.0% YoY
Profit After Tax
₹167 Cr
+10.0% YoY
Net Worth
₹1,169 Cr
+20.7% YoY
Total Assets
₹1,768 Cr
+54.7% YoY
Total Debt
₹450 Cr
+206.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24
Income statement
Revenue1,4461,020837
Revenue growth+41.7%+22.0%-
EBITDA315248181
EBITDA margin+21.8%+24.3%+21.6%
Profit before tax231194130
Net profit167152128
Net profit margin+11.6%+14.9%+15.3%
EPS (₹)14.7764.32452.32
Balance sheet
Total assets1,7681,1431,039
Net worth1,169968823
Total debt450147184
Cash & bank36712922.11
Net working capital1,038612644
Cash flow
Cash from operations50.392879.57
Cash from investing(53.91)(123)(45.01)
Cash from financing276(26.15)(31.55)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue25940856120558099.71
Revenue growth (YoY)-55.4%+309.6%----
Other income5.773.104.792.841.090.76
EBITDA43.951011598.70167(16.10)
EBITDA margin+17.0%+24.6%+28.3%+4.2%+28.9%-16.1%
Depreciation23.3617.0819.6017.9113.8112.32
Interest8.8610.7012.0810.806.983.61
Profit before tax17.5075.91132(17.17)148(31.27)
Tax9.8023.1736.01(2.57)40.89(7.33)
Net profit7.7052.7495.82(14.60)107(23.94)
EPS (₹)1.335.218.050.009.74(2.10)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue1,3139717563277761,271
Revenue growth+35.2%+28.4%+131.6%-57.9%-38.9%-
EBITDA24921717740.08319595
EBITDA margin+18.9%+22.3%+23.4%+12.3%+41.1%+46.8%
Profit before tax19818815222.85258549
Net profit14714612815.54187410
Net profit margin+11.2%+15.0%+16.9%+4.8%+24.1%+32.2%
EPS (₹)12.8361.98492.9368.97833.472,026.76
Balance sheet
Total assets1,4861,018921796791594
Net worth1,135990850739683335
Total debt34626.2070.2457.18105257
Cash & bank10911118.264.586.3915.87
Net working capital749537567488549377
Cash flow
Cash from operations(37.98)24937.7467.9097.78344
Cash from investing(256)(97.90)(31.44)(51.01)(86.72)(142)
Cash from financing292(17.35)(24.20)30.96(20.01)(192)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue24939943920057995.32
Revenue growth (YoY)-57.0%+319.0%----
Other income3.971.372.741.901.591.48
Total expenses190308332183445105
EBITDA58.6491.6410717.09134(9.64)
EBITDA margin+23.6%+22.9%+24.4%+8.5%+23.2%-10.1%
Depreciation13.998.429.859.738.757.41
Interest6.278.669.288.083.911.89
Profit before tax42.3575.9390.651.18123(17.46)
Tax10.9719.3024.970.1131.21(4.06)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 09 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue25940856120558099.71
Revenue growth (YoY)-55.4%+309.6%----
Other income5.773.104.792.841.090.76
EBITDA43.951011598.70167(16.10)
EBITDA margin+17.0%+24.6%+28.3%+4.2%+28.9%-16.1%
Depreciation23.3617.0819.6017.9113.8112.32
Interest8.8610.7012.0810.806.983.61
Profit before tax17.5075.91132(17.17)148(31.27)
Tax9.8023.1736.01(2.57)40.89(7.33)
Net profit7.7052.7495.82(14.60)107(23.94)
EPS (₹)1.335.218.050.009.74(2.10)
ParticularsFY 2025-26FY 2024-25FY 2023-24
Revenue1,4461,020837
Revenue growth+41.7%+22.0%-
Other income13.338.704.10
Total expenses1,131772656
Employee cost14510363.89
EBITDA315248181
EBITDA margin+21.8%+24.3%+21.6%
Depreciation63.6444.5541.01
Interest33.4717.6614.45
Profit before tax231194130
Tax66.9955.8546.09
Net profit167152128
Net profit margin+11.6%+14.9%+15.3%
EPS (₹)14.7764.32452.32
ParticularsFY 2025-26FY 2024-25FY 2023-24
Equity & liabilities
Share capital11.282.262.25
Reserves & surplus1,158966821
Shareholders' funds (net worth)1,169968823
Minority interest139(1.11)5.46
Secured loans33617.4166.40
Unsecured loans114130117
Total debt450147184
Total liabilities1,7681,1431,039
Assets
Gross block787485448
Net block536290289
Capital work in progress11.3227.331.58
Investments5.9845.575.99
Inventories449436315
Sundry debtors409272425
Cash & bank balances36712922.11
Loans & advances16093.2160.46
Total current assets1,385930823
Total current liabilities347318179
Net working capital1,038612644
Total assets1,7681,1431,039
ParticularsFY 2025-26FY 2024-25FY 2023-24
Opening cash63.23(75.07)(8.08)
Net cash from operating activities50.392879.57
Net cash from investing activities(53.91)(123)(45.01)
Net cash from financing activities276(26.15)(31.55)
Net change in cash273138(66.99)
Closing cash36712922.11
ParticularsFY 2025-26FY 2024-25FY 2023-24
Growth
Sales growth+41.7%+22.0%-
EBITDA growth+27.0%+37.0%-
PBT growth+18.9%+50.0%+9997.0%
Net income growth+10.0%+18.4%-
Profitability & leverage
Net income margin+11.4%+13.6%+10.0%
Return on capital employed+19.1%+19.5%+20.7%
Return on net worth+15.4%+15.5%+14.2%
Debt / equity0.280.180.20
Long-term debt / equity0.120.020.05
Interest cover13.328.6810.32
Efficiency & per share
Fixed asset turnover2.272.192.00
Inventory turnover3.272.722.53
Debtors turnover4.252.932.72
EPS (₹)14.7764.32452.32
Dividend per share (₹)0.000.000.00
Book value per share (₹)103.70429.253,651.42
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue24939943920057995.32
Revenue growth (YoY)-57.0%+319.0%----
Other income3.971.372.741.901.591.48
Total expenses190308332183445105
EBITDA58.6491.6410717.09134(9.64)
EBITDA margin+23.6%+22.9%+24.4%+8.5%+23.2%-10.1%
Depreciation13.998.429.859.738.757.41
Interest6.278.669.288.083.911.89
Profit before tax42.3575.9390.651.18123(17.46)
Tax10.9719.3024.970.1131.21(4.06)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue1,3139717563277761,271
Revenue growth+35.2%+28.4%+131.6%-57.9%-38.9%-
Other income7.726.376.528.105.111.48
Total expenses1,065754580286457676
Employee cost0.0065.6538.6034.0128.8177.81
EBITDA24921717740.08319595
EBITDA margin+18.9%+22.3%+23.4%+12.3%+41.1%+46.8%
Depreciation35.7326.3123.6019.3941.7512.03
Interest23.158.867.615.9424.8635.24
Profit before tax19818815222.85258549
Tax52.9248.2240.797.3170.57139
Net profit14714612815.54187410
Net profit margin+11.2%+15.0%+16.9%+4.8%+24.1%+32.2%
EPS (₹)12.8361.98492.9368.97833.472,026.76
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital11.282.262.252.252.252.02
Reserves & surplus1,123988847736681333
Shareholders' funds (net worth)1,135990850739683335
Secured loans33517.4125.5837.981.31157
Unsecured loans11.388.7944.6619.2010499.33
Total debt34626.2070.2457.18105257
Total liabilities1,4861,018921796791594
Assets
Gross block40733330026023466.17
Net block25721520918918254.81
Capital work in progress5.6217.601.580.000.00100
Investments31795.3553.7953.798.748.74
Inventories397410293328296265
Sundry debtors359228360173241211
Cash & bank balances10911118.264.586.3915.87
Loans & advances13977.7952.3810588.9096.91
Total current assets1,004827724611632589
Total current liabilities25429015712382.79213
Net working capital749537567488549377
Total assets1,4861,018921796791594
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash111(22.56)(4.65)(52.49)14.955.37
Net cash from operating activities(37.98)24937.7467.9097.78344
Net cash from investing activities(256)(97.90)(31.44)(51.01)(86.72)(142)
Net cash from financing activities292(17.35)(24.20)30.96(20.01)(192)
Net change in cash(1.84)133(17.91)47.84(8.94)9.58
Closing cash10911118.264.586.3915.87
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+35.2%+28.4%+131.6%-57.9%-38.9%-
EBITDA growth+14.7%+22.8%+340.6%-87.5%-46.3%-
PBT growth+5.1%+23.8%+564.7%-91.1%-53.1%+9997.0%
Net income growth+0.9%+13.7%+723.9%-91.7%-54.3%-
Revenue CAGR (3Y)+59.0%+7.8%-15.9%---
EBITDA CAGR (3Y)+83.8%-12.1%-33.3%---
Profitability & leverage
Net income margin+11.0%+14.4%+14.7%+4.8%+24.1%+32.2%
Return on capital employed+17.6%+20.3%+21.8%+3.6%+40.8%+127.4%
Return on net worth+13.6%+15.2%+16.1%+2.2%+36.8%+310.6%
Debt / equity0.180.050.080.110.362.47
Long-term debt / equity0.110.020.010.000.161.48
Interest cover10.874.654.9728.718.966.05
Efficiency & per share
Fixed asset turnover3.553.072.701.325.1721.09
Inventory turnover3.252.762.441.052.777.88
Debtors turnover4.483.302.831.583.4310.92
EPS (₹)12.8361.98492.9368.97833.472,026.76
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)100.63438.863,769.453,276.953,042.221,655.09

Investments & Acquisitions by Molbio Diagnostics

Molbio Diagnostics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Prognosys Medical Systems.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Prognosys Medical Systems
High-end medical devices for radiology and imaging are manufactured.
prognosysmedical.comBengaluru, India2003Feb 2023••••
Premium access

Complete acquisition details for Molbio Diagnostics

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Molbio Diagnostics

7 dated milestones of Molbio Diagnostics across 26 years, from founding to its latest funding, stage changes and deals.

  1. Founded Molbio Diagnostics is founded.
  2. Funding First funding round of $19.7M.
  3. Milestone Reaches Unicorn status.
  4. Milestone Reaches Minicorn status.
  5. Acquisition Acquires Prognosys Medical Systems.
  6. Funding Latest funding round, Grant,.
  7. IPO Lists on the stock exchange (IPO).

Web traffic of Molbio Diagnostics

The website of Molbio Diagnostics (molbiodiagnostics.com) receives about 7.1K visits a month.

  • Monthly visits
    7.1K

    ▼ 45.2% vs previous month

Similar websites

Websites whose visitors overlap most with Molbio Diagnostics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
annclinlabsci.org
annclinlabsci.org
100%
#1,002,863–
BD
bd.com
84%
1.2M#57,463View details
FIND Diagnostics
finddx.org
75%
27.9K#1,084,933View details
gomolecular.com
gomolecular.com
51%
–
biospectrumasia.com
biospectrumasia.com
51%
#773,792–
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Molbio Diagnostics

Motilal Oswal initiates coverage on Molbio Diagnostics stock with Buy, sees 21% upside. Here's why - The Economic Times
Economic Times • 1 month ago
Buy Molbio Diagnostics; target of Rs 1800: Motilal Oswal
Moneycontrol • 1 month ago
Molbio Diagnostics shares jump 5% as HDFC MF buys 1.99% stake via bulk deal | Newly listed stock up 71% from IPO price | Stock Market News
mint • 1 month ago
Motilal Oswal Alternates sells over 2% stake in Molbio Diagnostics for ₹306 cr - The HinduBusinessLine
Thehindubusinessline • 1 month ago
Molbio Diagnostics shares rally 9% as Jefferies initiates 'high conviction top pick' call for recently listed stock. Why is it bullish? - The Economic Times
Economic Times • 1 month ago
Recently listed Molbio Diagnostics share price falls 9%: Healthcare stock loses 18.5% in 2 days after blockbuster rally | Stock Market News
mint • 1 month ago
Molbio Diagnostics shares rally 30% in 2 days, jump 80% since debut. What lies ahead? - The Economic Times
Economic Times • 2 months ago
Saraswati Saree Depot Ltd leads gainers in 'B' group | Capital Market News - Business Standard
Business Standard • 2 months ago
Molbio Diagnostics hits 20% upper circuit on heavy volume; up 35% in 2 days | Markets News - Business Standard
Business Standard • 2 months ago
Molbio Diagnostics reports Q2 profit; Jayaswal Neco clarifies relationship; Morepen Labs expands capacity
Moneycontrol • 2 months ago
Premium access

Complete news archive for Molbio Diagnostics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Molbio Diagnostics

Molbio Diagnostics was founded in 2000 and raised its 1st funding round 20 years after it was founded.

Molbio Diagnostics is headquartered in Salcete, India. It is registered at Salcete, Goa, India.

Sriram Natarajan is the CEO of Molbio Diagnostics, as recorded in our data. They have also founded this company.

Molbio Diagnostics is a funded company, having raised a total of $123.98M across 4 funding rounds to date. The company's 1st funding round was a Series B of $19.73M, raised on Jan 2020.

Molbio Diagnostics has 714 employees.

The primary company behind Molbio Diagnostics, Molbio Diagnostics Limited, reported revenue of ₹1,459 Cr for FY 2026, up 42% year on year.

Developer of point-of-care molecular diagnostic platform for infectious disease detection. The solution includes Trueprep a fully automatic universal cartridge-based sample prep device, Prolab Atlus portable x-ray system, Thermalytix AI-based thermal scanning device, and Truelab, a real-time, quantitative micro-PCR analyzer that targets diseases like rifampicin resistance, COVID19, influenza, dengue, hepatitis, HPV, malaria, and others.

Molbio Diagnostics offers Truenat and Truenat Assays.

Yes, Molbio Diagnostics is publicly traded on NSE under the ticker symbol MOLBIO.

Molbio Diagnostics has made 1 acquisition, including Prognosys Medical Systems.

Molbio Diagnostics has 17 investors. Key investors include Motilal Oswal, Motilal Oswal Financial Services, Temasek, ACT Grants, and Motilal Oswal Private Equity.

The valuation of Molbio Diagnostics is $1.6B as of Sep 2022.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available